Get the Stockscreener App
141.00
3.01%
-4.38
Pre-market:
141.00
Insmed Inc stock is traded at $141.00, with a volume of 1.46M.
It is down -3.01% in the last 24 hours and up +6.92% over the past month.
Insmed Inc is a biopharmaceutical company transforming the lives of patients with serious and rare diseases. The company's first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), approved in the United States for the treatment of Mycobacterium Avium Complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. It is also developing Brensocatib, an oral reversible dipeptidyl peptidase 1 inhibitor for bronchiectasis and other neutrophil-mediated diseases, and Treprostinil Palmitil Inhalation Powder, an inhaled treprostinil prodrug for pulmonary hypertension linked to interstitial lung disease and pulmonary arterial hypertension.
See More
Previous Close:
$145.38
Open:
$144.97
24h Volume:
1.46M
Relative Volume:
0.46
Market Cap:
$29.80B
Revenue:
$398.11M
Net Income/Loss:
$-1.03B
P/E Ratio:
-24.78
EPS:
-5.69
Net Cash Flow:
$-868.57M
1W Performance:
-2.61%
1M Performance:
+6.92%
6M Performance:
+77.63%
1Y Performance:
+94.13%
1-Day Range:
$140.87
$145.56
1-Week Range:
$140.87
$146.71
52-Week Range:
$60.40
$149.08
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
141.00 | 30.73B | 398.11M | -1.03B | -868.57M | -5.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
376.62 | 97.36B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
576.98 | 60.19B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
458.37 | 59.56B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
729.76 | 44.94B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
329.84 | 36.14B | 3.81B | -644.79M | -669.77M | -6.24 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Assenagon Asset Management S.A. Buys 33,626 Shares of Insmed, Inc. $INSM - MarketBeat
Longboard Asset Management LP Acquires New Position in Insmed, Inc. $INSM - MarketBeat
Insmed Incorporated to Present Multiple Abstracts At the European Respiratory Society Congress 2025 - MarketScreener
Cystic Fibrosis Pipeline 2025: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Insmed Inc, AstraZeneca, Zambon, CSL Behring, Chiesi Farmaceutici - The Globe and Mail
Insmed to Present Phase 2b TPIP and Phase 3 ASPEN Trial Data at ERS Congress 2025 - geneonline.com
Insmed (INSM) Highlights Phase 2 and Phase 3 Trial Data at ERS 2025 Congress - GuruFocus
Insmed to Present Multiple Abstracts at the European Respiratory Society Congress 2025 - PR Newswire
Harbor Capital Advisors Inc. Sells 26,030 Shares of Insmed, Inc. $INSM - MarketBeat
Financiere des Professionnels Fonds d investissement inc. Makes New $452,000 Investment in Insmed, Inc. $INSM - MarketBeat
Primer: Insmed Inc (INSM US)Sep 2025 - Smartkarma
Weekly Trades: Will Insmed Incorporated outperform its industry peersMarket Activity Report & Risk Controlled Daily Plans - خودرو بانک
Strs Ohio Purchases Shares of 25,700 Insmed, Inc. $INSM - MarketBeat
Dividend Watch: Whats the beta of Insmed Incorporated stockMarket Trend Summary & Precise Swing Trade Alerts - خودرو بانک
Rep. Gilbert Ray Cisneros, Jr. Sells Insmed, Inc. (NASDAQ:INSM) Shares - MarketBeat
Signal Recap: Is Insmed Incorporated stock good for income investorsWeekly Volume Report & Precise Swing Trade Entry Alerts - khodrobank.com
Is Insmed Incorporated stock a smart retirement pick2025 Price Momentum & AI Powered Buy/Sell Recommendations - khodrobank.com
Insmed (NASDAQ:INSM) Insider Orlov S. Nicole Schaeffer Sells 76,520 Shares - MarketBeat
Melvin Md Sharoky Sells 10,000 Shares of Insmed (NASDAQ:INSM) Stock - MarketBeat
Insmed, Inc. $INSM Shares Bought by UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC - MarketBeat
Insmed (NASDAQ:INSM) Stock Price Down 3.4% Following Insider Selling - MarketBeat
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.51%
0.45%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):